Madrigal Pharmaceuticals Inc (MDGL) reports robust Q3 sales driven by Rezdiffra demand, while navigating increased SG&A ...

In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall ...

Novo's Rival Drug Shows Promise, But Madrigal's First-Mover Advantage Keeps Investors Hooked--What's Next for This Rising ...

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

Q3 2024 Earnings Call Transcript October 31, 2024 Madrigal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Jefferies analyst Akash Tewari maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target ...

B. Riley analyst Mayank Mamtani raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $236 from $194 and keeps a Neutral rating on the shares. Madrigal’s Q3 earnings “blowout” print ...

For the first time since 2021, the ninth-seeded Durango boys soccer team punched its ticket to the 4A state quarterfinals with a 3-1 win at No. 8 Montbello on Wednesday afternoon. The Demons scored ...

Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck ...

In the effort to expand approaches to treating Alzheimer’s beyond targeting amyloid, some companies have sought to target ...

Chief Executive Officer of Madrigal, Bill Sibold, highlighted the successful launch of Rezdiffra™ (resmetirom) in the U.S., emphasizing strong adoption by prescribers and increasing patient ...